62 completed, 35 unknown, 19 terminated, 17 recruiting. 64 Phase 2, 36 Not applicable, 24 Phase 3, 20 Phase 1, 5 Phase 4.
Follow Cytokine Release Syndrome: new trials by email Literature Review of Cytokine Release Syndrome trials Research Report on Cytokine Release Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RPM Signals in Outpatient CAR T Therapy Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome | Not yet recruiting | Current Health | 125 | 2026-12-01 | 2026-10-20 | |
| Wearable Core Body Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Outpatients Receiving CAR T-Cell Therapy TempShield Continuous Temperature Monitoring, Standard of Care - Myeloma | Not applicable | Not yet recruiting | Wake Forest University Health Sciences | 105 | 2026-12-01 | 2026-11-05 |
| CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia CLL-1-CD70 CAR-T Cell Injection - Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | Liping Dou | 12 | 2026-11-30 | 2026-10-27 |
| INfections in Patients Treated With CAR-T Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Not yet recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 290 | 2026-11-01 | 2026-07-20 | |
| Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp Dexamethasone - Uveal Melanoma, Metastatic | Phase 2 | Withdrawn | University of California, San Diego | 2026-11-01 | 2026-11-06 | |
| Pre-emptive Anakinra for Cytokine Event Reduction Anakinra (Kineret®) - B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy | Phase 1 / Phase 2 | Withdrawn | Kevin McNerney | 2026-10-01 | 2026-08-13 | |
| CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia SL1CC Injection - Relapsed/Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) | Phase 1 | Not yet recruiting | Liping Dou | 12 | 2026-10-01 | 2026-10-02 |
| Real-World Use of Tarlatamab in Chinese Patients With Small-Cell Lung Cancer Tarlatamab - Extensive-Stage Small Cell Lung Cancer | Active not recruiting | Ruijin Hospital | 26 | 2026-08-03 | 2026-10-21 | |
| Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Cytokine Release Syndrome, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Naresh Bumma | 35 | 2026-07-17 | 2026-10-06 |
| Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) Linvoseltamab, Tocilizumab - Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 4 | Recruiting | Regeneron Pharmaceuticals | 30 | 2026-07-15 | 2026-10-27 |
| Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) Experimental Intervention - B Cell Malignancies, B-cell Leukemia | Phase 1 | Not yet recruiting | University Hospital, Basel, Switzerland | 12 | 2026-06-01 | 2025-12-24 |
| Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event TempTraq, VitalTraq - Cytokine Release Syndrome, Neoplasms | Not applicable | Enrolling by invitation | National Cancer Institute (NCI) | 136 | 2026-05-27 | 2026-06-25 |
| Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis Etoposide (Early strategy), Etoposide (Delayed strategy) - Hemophagocytic Lymphohistiocytosis | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 176 | 2026-04-01 | 2026-04-23 |
| Jafron Cytokine Adsorber During Pediatric Open-Heart Surgeries Hemoadsorption - Cardiac Surgery Recovery, Inflammation | Not applicable | Not yet recruiting | Centre Hospitalier Universitaire Vaudois | 20 | 2026-03-01 | 2026-02-10 |
| NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) Talikabtagene Autoleucel - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | Health Institutes of Turkey | 40 | 2025-09-11 | 2026-03-30 |
| Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy Home Automated Telemanagement (HAT) Patient Unit - Lymphoma, Myeloma | Not applicable | Recruiting | University of Utah | 40 | 2025-09-01 | 2026-02-05 |
| A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma Siltuximab - CRS - Cytokine Release Syndrome, Myeloma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-08-10 | 2025-08-06 |
| Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study Methylene Blue - Cytokine Release Syndrome, ICANS | Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 18 | 2025-06-28 | 2025-09-11 |
| Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma Elranatamab injection - Refractory Multiple Myeloma | Phase 2 | Recruiting | Ontario Clinical Oncology Group (OCOG) | 40 | 2025-03-28 | 2026-09-28 |
| Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL Obinutuzumab, Glofitamab, Gemcitabine - Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma | Phase 2 | Recruiting | Hoffmann-La Roche | 130 | 2025-03-05 | 2026-11-10 |
Showing 20 of 163. Sign in to see all of them.
COVID-19 (84) · Respiratory Distress Syndrome (21) · Coronavirus Infections (19) · Pneumonia (14) · Inflammation (10) · Sepsis (10) · Multiple Myeloma (9) · Recurrence (7) · Lymphohistiocytosis, Hemophagocytic (6) · Lymphoma, Non-Hodgkin (6) · Respiratory Insufficiency (6) · Severe Acute Respiratory Syndrome (6) · Shock, Septic (6) · Lymphoma, B-Cell (5)
Pathologic Processes (163) · Pathological Conditions, Signs and Symptoms (163) · Shock (162) · Systemic Inflammatory Response Syndrome (162) · Inflammation (153) · Infections (103) · Respiratory Tract Diseases (91) · Lung Diseases (90) · Virus Diseases (90) · RNA Virus Infections (88) · Coronaviridae Infections (87) · Nidovirales Infections (87) · Respiratory Tract Infections (85) · Pneumonia, Viral (84) · Pneumonia (71)
tocilizumab (14) · Standard of Care (9) · Interleukin 1 Receptor Antagonist Protein (6) · ruxolitinib (6) · siltuximab (5) · Adrenal Cortex Hormones (4) · Dexamethasone (4) · Plasma Exchange (4) · Calcifediol (3) · Cyclophosphamide (3) · Etoposide (3) · Infliximab (3) · Saline Solution (3) · fludarabine (3) · AP 1903 reagent (2)
Ain Shams University (4) · Incyte Corporation (3) · Novartis Pharmaceuticals (3) · 101 Therapeutics (2) · Alexandria University (2) · Applied Science Private University (2) · Dr. Alexander Supady (2) · Hadassah Medical Organization (2) · Hospital Universitario Dr. Jose E. Gonzalez (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Liping Dou (2) · Masonic Cancer Center, University of Minnesota (2) · UNC Lineberger Comprehensive Cancer Center (2) · UNICEF (2) · University Hospital, Basel, Switzerland (2)
United States (49) · Germany (11) · Spain (11) · China (10) · Mexico (10) · Egypt (8) · France (8) · Brazil (7) · Italy (7) · Switzerland (5) · Turkey (Türkiye) (4) · United Kingdom (4) · Austria (3) · Canada (3) · India (3)
Neven Sarhan, PhD (3) · Alexander Supady, Dr., MPH (2) · Joaquin Espinosa, PhD (2) · Mahmoud S Abu-Samak, PhD (2) · Agung Putra, Assoc.Prof (1) · Alexander Zoufaly, MD (1) · Ali Dehghan-Manshadi, MD (1) · Amato De Monte (1) · Amitkumar Mehta, MD (1) · Amr K Ahmed (1) · Anders Kjellberg, MD (1) · Andreas Holbro, Prof. Dr. (1) · Andrew Olson, M.D. (1)
PMID 32192578, PMID 31986264, PMID 32091533, PMID 32167524, PMID 32234467, PMID 32283152, PMID 10415784, PMID 12563677, PMID 12781536, PMID 14719037, PMID 15657466, PMID 15663512, PMID 15919935, PMID 16213065, PMID 16322745, PMID 16368644, PMID 16614252, PMID 17031779, PMID 17181919, PMID 17344507, PMID 17485224, PMID 17487675, PMID 1750226, PMID 17921398, PMID 17943116, PMID 18097874, PMID 18550812, PMID 19275682, PMID 19397687, PMID 19430490, PMID 19453649, PMID 19785746, PMID 19998041, PMID 20093825, PMID 21118369, PMID 21131395, PMID 21317636, PMID 21445287, PMID 21533222, PMID 22028728, PMID 22381456, PMID 22545014, PMID 22731679, PMID 22837003, PMID 22907572, PMID 24348219, PMID 24572573, PMID 24804272, PMID 24876563, PMID 25190079
2023 (1), 2025 (1), K12CA120780 (1), K12TR005104 (1), P30CA138292 (1), R44CA295189 (1)